ClearBridge Investments, an investment management firm, published its “Small Cap Strategy” first quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Small Cap Strategy outperformed its Russell 2000 Index benchmark during the first quarter. On an absolute basis, the Strategy had losses across six of the 11 sectors in which it was invested during the quarter. The leading detractors were the consumer discretionary, IT, and financial sectors, while the leading contributors were the energy and health care sectors. Try to spend some time taking a look at the fund’s top 5 holdings to be informed about their best picks for 2022.
In its Q1 2022 investor letter, Clearbridge Investments Small Cap Strategy mentioned Lantheus Holdings, Inc. (NASDAQ:LNTH) and explained its insights for the company. Founded in 1956, Lantheus Holdings, Inc. (NASDAQ:LNTH) is a Billerica, Massachusetts-based diagnostic medical imaging agents and products developer and manufacturer with a $4.1 billion market capitalization. Lantheus Holdings, Inc. (NASDAQ:LNTH) delivered a 108.65% return since the beginning of the year, while its 12-month returns are up by 176.51%. The stock closed at $60.28 per share on April 15, 2022.
Here is what Clearbridge Investments Small Cap Strategy has to say about Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q1 2022 investor letter:
“While companies with immature business models and no profits exist throughout the market, there are certain sectors where they congregate more easily, such as health care. As access to cheap capital recedes, however, many of these specialty drug and biotech companies will likely find it challenging to dismiss long periods of unprofitability. While we have had limited exposure in the sector, our focus on finding high-quality companies at attractive valuations has yielded positive results. For example, Lantheus Holdings (NASDAQ:LNTH) is a global leader in medical diagnostic imaging whose core business suffered during the COVID-19 pandemic due to a dramatic decline in hospital visits. As hospitals return to a level of normalcy, Lantheus’s core business has rebounded. Additionally, in late 2021 the company received approval for its new radio-pharmacological drug, Pylarify, for the treatment of prostate cancer, and initial sales have been well ahead of expectations. We believe it has a strong future in oncology diagnosis and treatment. As a result, Lantheus was our strongest individual performer for the first quarter.”
national-cancer-institute–Ln-tYivJM4-unsplash
Our calculations show that Lantheus Holdings, Inc. (NASDAQ:LNTH) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Lantheus Holdings, Inc. (NASDAQ:LNTH) was in 15 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 14 funds in the previous quarter. Lantheus Holdings, Inc. (NASDAQ:LNTH) delivered a 127.47% return in the past 3 months. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q1 page.
Disclosure: None. This article is originally published at Insider Monkey.
